In this real-world observational study, we compared two treatment strategies in 86 SLE patients: personalized therapy with telitacicept in BAFF/APRIL double-positive patients (n = 14) versus conventional belimumab therapy without expression testing (n = 72). Here, TNFSF13 is linked to systemic lupus erythematosus.